1. Q2 2025 Performance Analysis: What Drove the Earnings Surprise?

Pharmgen Science recorded KRW 45.8 billion in revenue, KRW 3.3 billion in operating profit, and KRW 3.8 billion in net profit in Q2 2025. This represents significant growth compared to the previous quarter and surpasses market expectations. This strong performance is attributed to the steady growth of the pharmaceutical business and the success of its healthcare diversification strategy. In particular, the launch of innovative products such as ‘Vitaing Sustained Vitamin C’ and the strengthening of online channels have led to notable achievements in the healthcare business segment.

2. Pharmgen Science’s Fundamentals: Financial Stability and Growth Drivers

Pharmgen Science has improved its financial health by reducing its debt through measures such as the repayment of convertible bonds. However, the debt-to-equity ratio, still over 100%, requires continuous management. Meanwhile, the company continues its R&D efforts on its digestive system drug pipeline (inflammatory bowel disease, gastroesophageal reflux disease, liver-specific MRI contrast agent). Notably, the liver-specific MRI contrast agent has been selected as a national new drug development project, positioning it as a future growth driver. Investments in securing future growth engines, such as a 1-month sustained-release obesity treatment and intra-articular injections, are also ongoing.

3. Future Stock Price Outlook and Investment Strategies

In the short term, Pharmgen Science’s stock price is expected to gain momentum due to the earnings surprise. In the mid to long term, the visibility of R&D investment results and cost management capabilities will be key factors determining the stock’s direction. Furthermore, continuous monitoring of exchange rate volatility is necessary as the rising KRW/USD exchange rate could lead to increased import costs of raw materials. Investors should make investment decisions based on a comprehensive consideration of Pharmgen Science’s new drug development achievements, healthcare business growth, and overall market environment changes.